- Home
- CGNT vs CERT Comparison
CGNT vs CERT Comparison
Compare CGNT & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGNT | CERT |
|---|---|---|
| Founded | 2020 | 2008 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Retail: Computer Software & Peripheral Equipment |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 768.2M | 808.9M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CGNT | CERT |
|---|---|---|
| Price | $8.33 | $5.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $13.50 | $11.67 |
| AVG Volume (30 Days) | 916.6K | ★ 4.0M |
| Earning Date | 06-10-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,838,000.00 |
| Revenue This Year | $13.73 | $4.18 |
| Revenue Next Year | $10.45 | $5.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $6.29 | $4.45 |
| 52 Week High | $12.31 | $13.88 |
Technical Indicators
Market Signals| Indicator | CGNT | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 37.78 | 55.12 |
| Support Level | $7.97 | $5.08 |
| Resistance Level | $8.84 | $6.34 |
| Average True Range (ATR) | 0.34 | 0.35 |
| MACD | -0.09 | 0.03 |
| Stochastic Oscillator | 30.57 | 60.16 |
Price Performance
Historical ComparisonAbout CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.